Iranian Journal of Medical Sciences

Document Type : Original Article(s)


1 Department of Neurology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

2 Department of Neurology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

3 Department of Clinical Pharmacy, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran



Background: There is no definite recommendation for melatonin supplementation in episodic migraine. This study aimed to evaluate the effect of melatonin on reducing the frequency and severity of migraine attacks.
Methods: This randomized, double-blind clinical trial was conducted at Golestan Hospital of Ahvaz, Iran, in 2021. A total of 60 patients with episodic migraine were randomly assigned into 2 groups of receiving 3 mg melatonin (intervention group; n=30) or the same dose of placebo (control group; n=30) along with baseline therapy (propranolol 20 mg, BID) for two months. The attack frequency, attack duration, attack severity (based on VAS), the number of analgesic intakes, drug complications, Migraine Disability Assessment score (MIDAS), and Pittsburgh sleep quality index (PSQI) were evaluated at baseline and in the first, second, third, and fourth months of follow-up. The independent t test, chi-square, and analysis of variance (ANOVA) with repeated measures were used to compare variables between the two groups. 
Results: In both groups, the frequency, duration, and severity of attacks, taking analgesics, MIDAS, and PSQI scores during follow-up decreased significantly (P<0.001). After treatment, the mean frequency (P=0.032) and duration of attacks (P=0.001), taking analgesic (P<0.001), and MIDAS (P<0.001) and PSQI scores (P<0.001) in the melatonin group were lower than placebo. Only the attack severity was not significantly different between the two groups (P=0.126). Side effects were observed in two patients (6.7%) in the melatonin group and one patient (3.3%) in the placebo group (P>0.999).
Conclusion: Our study shows that melatonin was more efficacious than the placebo in the reduction of frequency and duration of migraine attacks. It was equally safe as the placebo and might be effective in the preventive treatment of episodic migraine in adults.
Trial registration number: IRCT20190107042264N5.


  1. Ashina M. Migraine. N Engl J Med. 2020;383:1866-76. doi: 10.1056/NEJMra1915327. PubMed PMID: 33211930.
  2. Arnold M. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd ed. Cephalalgia. 2018;38:1-211. doi: 10.1177/0333102417738202. PubMed PMID: 29368949.
  3. Tseng PT, Yang CP, Su KP, Chen TY, Wu YC, Tu YK, et al. The association between melatonin and episodic migraine: A pilot network meta-analysis of randomized controlled trials to compare the prophylactic effects with exogenous melatonin supplementation and pharmacotherapy. J Pineal Res. 2020;69:e12663. doi: 10.1111/jpi.12663. PubMed PMID: 32347977.
  4. Aguilar-Shea AL, Membrilla Md JA, Diaz-de-Teran J. Migraine review for general practice. Aten Primaria. 2022;54:102208. doi: 10.1016/j.aprim.2021.102208. PubMed PMID: 34798397; PubMed Central PMCID: PMCPMC8605054.
  5. Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17:501-14. doi: 10.1038/s41582-021-00509-5. PubMed PMID: 34145431; PubMed Central PMCID: PMCPMC8321897
  6. Jackson JL, Kuriyama A, Kuwatsuka Y, Nickoloff S, Storch D, Jackson W, et al. Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. PLoS One. 2019;14:e0212785. doi: 10.1371/journal.pone.0212785. PubMed PMID: 30893319; PubMed Central PMCID: PMCPMC6426199.
  7. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017;97:553-622. doi: 10.1152/physrev.00034.2015. PubMed PMID: 28179394; PubMed Central PMCID: PMCPMC5539409.
  8. Karsan N, Goadsby PJ. Biological insights from the premonitory symptoms of migraine. Nat Rev Neurol. 2018;14:699-710. doi: 10.1038/s41582-018-0098-4. PubMed PMID: 30448858.
  9. Kelman L, Rains JC. Headache and sleep: examination of sleep patterns and complaints in a large clinical sample of migraineurs. Headache. 2005;45:904-10. doi: 10.1111/j.1526-4610.2005.05159.x. PubMed PMID: 15985108.
  10. Calhoun AH, Ford S, Finkel AG, Kahn KA, Mann JD. The prevalence and spectrum of sleep problems in women with transformed migraine. Headache. 2006;46:604-10. doi: 10.1111/j.1526-4610.2006.00410.x. PubMed PMID: 16643555.
  11. Karsan N, Goadsby PJ. Imaging the Premonitory Phase of Migraine. Front Neurol. 2020;11:140. doi: 10.3389/fneur.2020.00140. PubMed PMID: 32269547; PubMed Central PMCID: PMCPMC7109292.
  12. Wilson S, Anderson K, Baldwin D, Dijk DJ, Espie A, Espie C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update. J Psychopharmacol. 2019;33:923-47. doi: 10.1177/0269881119855343. PubMed PMID: 31271339.
  13. Long R, Zhu Y, Zhou S. Therapeutic role of melatonin in migraine prophylaxis: A systematic review. Medicine (Baltimore). 2019;98:e14099. doi: 10.1097/MD.0000000000014099. PubMed PMID: 30653130; PubMed Central PMCID: PMCPMC6370052.
  14. Alstadhaug KB, Odeh F, Salvesen R, Bekkelund SI. Prophylaxis of migraine with melatonin: a randomized controlled trial. Neurology. 2010;75:1527-32. doi: 10.1212/WNL.0b013e3181f9618c. PubMed PMID: 20975054.
  15. Society IH. Headache Classification Committee of the International Headache ociety (IHS); The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2013;33:629-808. doi: 10.1177/0333102413485658. PubMed PMID: 23771276.
  16. Olesen J, Lipton RB. Migraine classification and diagnosis. International Headache Society criteria. Neurology. 1994;44:S6-10. PubMed PMID: 8008227.
  17. Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56:S20-8. doi: 10.1212/wnl.56.suppl_1.s20. PubMed PMID: 11294956.
  18. Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193-213. doi: 10.1016/0165-1781(89)90047-4. PubMed PMID: 2748771.
  19. Liampas I, Siokas V, Brotis A, Vikelis M, Dardiotis E. Endogenous Melatonin Levels and Therapeutic Use of Exogenous Melatonin in Migraine: Systematic Review and Meta-Analysis. Headache. 2020;60:1273-99. doi: 10.1111/head.13828. PubMed PMID: 32352572.
  20. Ebrahimi-Monfared M, Sharafkhah M, Abdolrazaghnejad A, Mohammadbeigi A, Faraji F. Use of melatonin versus valproic acid in prophylaxis of migraine patients: A double-blind randomized clinical trial. Restor Neurol Neurosci. 2017;35:385-93. doi: 10.3233/RNN-160704. PubMed PMID: 28800342.
  21. Goncalves AL, Martini Ferreira A, Ribeiro RT, Zukerman E, Cipolla-Neto J, Peres MF. Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. J Neurol Neurosurg Psychiatry. 2016;87:1127-32. doi: 10.1136/jnnp-2016-313458. PubMed PMID: 27165014; PubMed Central PMCID: PMCPMC5036209.
  22. Ali MMM, Humadi SA, Al-Jaff AN. Clinical evaluation of melatonin alone and in combination with pizotifen in the prophylaxis of migraine. Iraqi J Pharm Sci. 2007;16:1-7. doi: 10.31351/vol16iss1pp1-7.
  23. Gelfand AA, Qubty W, Patniyot I, Grimes B, Pletcher MJ, Goadsby PJ, et al. Home-Based Trials in Adolescent Migraine: A Randomized Clinical Trial. JAMA Neurol. 2017;74:744-5. doi: 10.1001/jamaneurol.2017.0285. PubMed PMID: 28437521; PubMed Central PMCID: PMCPMC5822205.
  24. Mohammadyahya E, Sarraf P, Javadian N, Shariat M, Bitarafan S, Tafakhori A. Melatonin as a potential prophylactic therapy for menstrual-related migraine headache: a randomized clinical trial. Archives of Neuroscience. 2020;7. doi: 10.5812/ans.94375.
  25. Danilov AB, Danilov AB, Kurushina OV, Shestel EA, Zhivolupov SA, Latysheva NV. Safety and Efficacy of Melatonin in Chronic Tension-Type Headache: A Post-Marketing Real-World Surveillance Program. Pain Ther. 2020;9:741-50. doi: 10.1007/s40122-020-00207-y. PubMed PMID: 33067764; PubMed Central PMCID: PMCPMC7648782.
  26. Fallah R, Fazelishoroki F, Sekhavat L. A Randomized Clinical Trial Comparing the Efficacy of Melatonin and Amitriptyline in Migraine Prophylaxis of Children. Iran J Child Neurol. 2018;12:47-54. PubMed PMID: 29379562; PubMed Central PMCID: PMCPMC5760673.
  27. Srinivasan V, Lauterbach EC, Ho KY, Acuna-Castroviejo D, Zakaria R, Brzezinski A. Melatonin in antinociception: its therapeutic applications. Curr Neuropharmacol. 2012;10:167-78. doi: 10.2174/157015912800604489. PubMed PMID: 23204986; PubMed Central PMCID: PMCPMC3386506.
  28. Wilhelmsen M, Amirian I, Reiter RJ, Rosenberg J, Gogenur I. Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies. J Pineal Res. 2011;51:270-7. doi: 10.1111/j.1600-079X.2011.00895.x. PubMed PMID: 21615490.
  29. Goadsby PJ, Lipton RB, Ferrari MD. Migraine--current understanding and treatment. N Engl J Med. 2002;346:257-70. doi: 10.1056/NEJMra010917. PubMed PMID: 11807151.
  30. Mungoven TJ, Henderson LA, Meylakh N. Chronic Migraine Pathophysiology and Treatment: A Review of Current Perspectives. Front Pain Res (Lausanne). 2021;2:705276. doi: 10.3389/fpain.2021.705276. PubMed PMID: 35295486; PubMed Central PMCID: PMCPMC8915760.
  31. Ansari M, Karkhaneh A, Kheirollahi A, Emamgholipour S, Rafiee MH. The effect of melatonin on gene expression of calcitonin gene-related peptide and some proinflammatory mediators in patients with pure menstrual migraine. Acta Neurol Belg. 2017;117:677-85. doi: 10.1007/s13760-017-0803-x. PubMed PMID: 28584969.